Hyperparathyroidism Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study of SHR6508 in Secondary Hyperparathyroidism
Condition: Secondary Hyperparathyroidism Interventions: Drug: SHR6508; Drug: Cinacalcet Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
